cardiovascular diseases

News

The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia and Braveheart the latest to make their intentions known.

News

Up to 280,000 people with heart failure could soon be eligible for NHS treatment with Bayer's Kerendia, following new NICE guidance.

News

People who have a heart attack are more likely to have microplastics in their blood, adding to evidence that plastic pollution may be a health issue.

News

Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq as it advances its spin on CRISPR-based therapeutics.

News

Ionis' Tryngolza has been approved for severe hypertriglyceridaemia, opening the door to what the company thinks could be a $3bn market opportunity.

News

Cardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated.